Cargando…
P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429612/ http://dx.doi.org/10.1097/01.HS9.0000873248.60171.71 |
| _version_ | 1784779508638810112 |
|---|---|
| author | F., GALACTÉROS E., VOSKARIDOU A., HABIBI G., CANNAS L., JOSEPH G., LOKO M., DE MONTALEMBERT |
| author_facet | F., GALACTÉROS E., VOSKARIDOU A., HABIBI G., CANNAS L., JOSEPH G., LOKO M., DE MONTALEMBERT |
| author_sort | F., GALACTÉROS |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429612 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94296122022-08-31 P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? F., GALACTÉROS E., VOSKARIDOU A., HABIBI G., CANNAS L., JOSEPH G., LOKO M., DE MONTALEMBERT Hemasphere Poster Presentations Lippincott Williams & Wilkins 2022-08-16 /pmc/articles/PMC9429612/ http://dx.doi.org/10.1097/01.HS9.0000873248.60171.71 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Presentations F., GALACTÉROS E., VOSKARIDOU A., HABIBI G., CANNAS L., JOSEPH G., LOKO M., DE MONTALEMBERT P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_full | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_fullStr | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_full_unstemmed | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_short | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_sort | p-090: is a dedicated marketing approval of hydroxyurea in sickle cell disease may increase the clinical benefit of the drug? |
| topic | Poster Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429612/ http://dx.doi.org/10.1097/01.HS9.0000873248.60171.71 |
| work_keys_str_mv | AT fgalacteros p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT evoskaridou p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT ahabibi p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT gcannas p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT ljoseph p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT gloko p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT mdemontalembert p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug |